Day: April 9, 2026

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) — Paloma Acquisition Corp I (Nasdaq: PALOU) (the “Company”) today announced that, commencing on April 13, 2026, holders of the units (the “Units”) sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (the “Ordinary Shares”) and warrants (the “Warrants”) included in the Units. The Ordinary Shares and Warrants received from the separated Units will trade on the Nasdaq Global Market (“Nasdaq”) under the symbols “PALO” and “PALOW”, respectively. Units that are not separated will continue to trade on Nasdaq under the symbol “PALOU”. Holders of Units will need to have their brokers contact Efficiency INC., the Company’s transfer agent, in order to separate the Units into Ordinary Shares and Warrants. The Company was formed for the purpose...

Quarterly Production of 45,776 oz AuEq1 Closing cash and bullion $362 million – $130 million increase from DecemberQuarterly gold production of 45,776 AuEq1 oz, comprised of:Mine Group Q3(1 Jan – 31 Mar 2026) Group YTD2(1 Jul – 31 March 2026)  ProductionTomingley 21,652 Au oz 62,076 Au ozCosterfield 10,584 Au oz377 Sb t11,691 AuEq oz 29,986 Au oz842 Sb t32,869 AuEq ozBjörkdal 12,433 Au oz 30,901 Au ozConsolidated 44,669 Au oz377 Sb t45,776 AuEq oz 122,963 Au oz842 Sb t125,846 AuEq oz  SalesConsolidated 42,550 Au oz280 Sb t43,373 AuEq oz 119,596 Au oz829 Sb t122,416 AuEq ozCash, bullion and listed investment balance of $374 million.Increase of $128 million from the previous quarter. Alkane has cash & bullion of $362 million, and pro forma liquidity of $472 million when including an undrawn $110...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California. Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”) will be presented. The payload of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC50 ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the payload has excellent selectivity. By conjugating this potent payload with an anti-EGFR antibody via a cleavable linker, the ATTC compound HMPL-A580...